The Nordic SentiMag trial: a comparison of super paramagnetic iron oxide (SPIO) nanoparticles versus Tc99 and patent blue in the detection of sentinel node (SN) in patients with breast cancer and a meta-analysis of earlier studies-Reference-Cited by-同舟云学术

The Nordic SentiMag trial: a comparison of super paramagnetic iron oxide (SPIO) nanoparticles versus Tc99 and patent blue in the detection of sentinel node (SN) in patients with breast cancer and a meta-analysis of earlier studies

Published:2016-04-27 Issue:2 Volume:157 Page:281-294
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Karakatsanis Andreas,Christiansen Peer Michael,Fischer Lone,Hedin Christina,Pistioli Lida,Sund Malin,Rasmussen Nils Ryegaard,Jørnsgård Hjørdis,Tegnelius Daniel,Eriksson Staffan,Daskalakis Kosmas,Wärnberg Fredrik,Markopoulos Christos J.,Bergkvist Leif

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-016-3809-9.pdf

Reference35 articles.

1. Mansel RE, Fallowfield L, Kissin M et al (2006) Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 98:599–609. doi: 10.1093/jnci/djj158

2. Ferrari A, Rovera F, Dionigi P, Limonta G, Marelli M, Besana Ciani I, Bianchi V, Vanoli C, Dionigi R (2006) Sentinel lymph node biopsy as the new standard of care in the surgical treatment for breast cancer. Expert Rev Anticancer Ther 6:1503–1515. doi: 10.1586/14737140.6.10.1503

3. Lyman GH, Temin S, Edge SB, Newman LA, Turner RR, Weaver DL, Benson AB III, Bosserman LD, Burstein HJ, Cody H III, Hayman J, Perkins CL, Podoloff DA, Giuliano AE, American Society of Clinical Oncology Clinical Practice (2014) Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 32:1365–1383. doi: 10.1200/JCO.2013.54.1177

4. Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M, Harris JR, Karn T, Liedtke C, Mauri D, Rouzier R, Ruckhaeberle E, Semiglazov V, Symmans WF, Tutt A, Pusztai L (2012) Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol 19:1508–1516. doi: 10.1245/s10434-011-2108-2

5. Straver ME, Meijnen P, van Tienhoven G et al (2010) Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial. Ann Surg Oncol 17:1854–1861. doi: 10.1245/s10434-010-0945-z

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of Superparamagnetic Iron Oxide Particles in Sentinel Node Biopsy—Evaluation of Its Effects on Breast MRI, Full‐Field Digital Mammography, and Contrast‐Enhanced Mammography;physica status solidi (a);2024-07-23

2. Skin Staining After Injection of Superparamagnetic Iron Oxide for Sentinel Lymph Node Dissection: A Retrospective Study of Two Protocols for Injection and Long-Term Follow-Up;European Journal of Breast Health;2024-07-01

3. Magnetic procedure for sentinel lymph node detection and evaluation of metastases: design and rationale of the Lowmag trial;BMC Methods;2024-06-17

4. Selective omission of sentinel lymph node biopsy in mastectomy for ductal carcinoma in situ: identifying eligible candidates;Breast Cancer Research;2024-04-12

5. Impact of low dose superparamagnetic iron oxide tracer for sentinel node biopsy in breast conserving treatment on susceptibility artefacts on magnetic resonance imaging and contrast enhanced mammography;Surgical Oncology;2024-04